Comparisons of IEI-related complications in transplanted and matched non-transplanted patients with CID
| Complications at baseline . | All patients (n = 212) . | No alloSCT (n = 153) . | alloSCT (n = 59) . | P value . |
|---|---|---|---|---|
| Infections | ||||
| Bacterial infection | 101 (48%) | 60 (39%) | 41 (69%) | <.001∗ |
| Viral infection† | 32 (15%) | 7 (5%) | 25 (42%) | <.001∗ |
| Parasitic infection | 8 (4%) | 2 (1%) | 6 (10%) | .007∗ |
| Invasive aspergillosis | 11 (5%) | 5 (3%) | 6 (10%) | .042∗ |
| Autoimmune cytopenia | ||||
| Autoimmune neutropenia | 27 (14%) | 19 (12%) | 8 (18%) | .327 |
| Autoimmune hemolytic anemia | 47 (23%) | 42 (27%) | 5 (10%) | .011∗ |
| Autoimmune thrombocytopenia | 35 (17%) | 28 (18%) | 7 (12%) | .258 |
| Colitis | 43 (20%) | 29 (19%) | 14 (24%) | .438 |
| Granuloma | 28 (13%) | 21 (14%) | 7 (12%) | .72 |
| Liver involvement‡ | 27 (13%) | 19 (12%) | 8 (14%) | .823 |
| Interstitial pulmonary involvement§ | 25 (12%) | 23 (15%) | 2 (3%) | .017∗ |
| Hemophagocytic syndrome | 14 (7%) | 8 (5%) | 6 (10%) | .194 |
| Vasculitis | 6 (3%) | 3 (2%) | 3 (5%) | .351 |
| Malignancy | ||||
| Lymphoid proliferation | 70 (33%) | 48 (31%) | 22 (37%) | .412 |
| Myeloid malignancy | 2 (1%) | 1 (1%) | 1 (2%) | .48 |
| Solid cancer | 11 (5%) | 8 (5%) | 3 (5%) | 1 |
| Complications at baseline . | All patients (n = 212) . | No alloSCT (n = 153) . | alloSCT (n = 59) . | P value . |
|---|---|---|---|---|
| Infections | ||||
| Bacterial infection | 101 (48%) | 60 (39%) | 41 (69%) | <.001∗ |
| Viral infection† | 32 (15%) | 7 (5%) | 25 (42%) | <.001∗ |
| Parasitic infection | 8 (4%) | 2 (1%) | 6 (10%) | .007∗ |
| Invasive aspergillosis | 11 (5%) | 5 (3%) | 6 (10%) | .042∗ |
| Autoimmune cytopenia | ||||
| Autoimmune neutropenia | 27 (14%) | 19 (12%) | 8 (18%) | .327 |
| Autoimmune hemolytic anemia | 47 (23%) | 42 (27%) | 5 (10%) | .011∗ |
| Autoimmune thrombocytopenia | 35 (17%) | 28 (18%) | 7 (12%) | .258 |
| Colitis | 43 (20%) | 29 (19%) | 14 (24%) | .438 |
| Granuloma | 28 (13%) | 21 (14%) | 7 (12%) | .72 |
| Liver involvement‡ | 27 (13%) | 19 (12%) | 8 (14%) | .823 |
| Interstitial pulmonary involvement§ | 25 (12%) | 23 (15%) | 2 (3%) | .017∗ |
| Hemophagocytic syndrome | 14 (7%) | 8 (5%) | 6 (10%) | .194 |
| Vasculitis | 6 (3%) | 3 (2%) | 3 (5%) | .351 |
| Malignancy | ||||
| Lymphoid proliferation | 70 (33%) | 48 (31%) | 22 (37%) | .412 |
| Myeloid malignancy | 2 (1%) | 1 (1%) | 1 (2%) | .48 |
| Solid cancer | 11 (5%) | 8 (5%) | 3 (5%) | 1 |
EBV, Epstein-Barr virus.
Significant at P < .05.
Viral infections included extensive warts, EBV-associated ulcers, complicated VZV infection, HPV-CIN, EBV viremia, and varicella without complication, herpesvirus, and HPV-CIN in nontransplanted patients.
Liver involvement included nodular regenerative hyperplasia, sclerosing cholangitis, and 1 patient with hepatitis T cell infiltration and another with EBV hepatitis.
Lung involvement included 9 of 23 nontransplanted patients with CTLA-4/LRBA deficiency.